Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nalidixic acid
Drug ID BADD_D01521
Description Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Indications and Usage For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.
Marketing Status approved; investigational
ATC Code J01MB02
DrugBank ID DB00779
KEGG ID D00183
MeSH ID D009268
PubChem ID 4421
TTD Drug ID D07JGT
NDC Product Code Not Available
UNII 3B91HWA56M
Synonyms Nalidixic Acid | Acid, Nalidixic | Nalidixin | Nalidixate Sodium Anhydrous | Anhydrous, Nalidixate Sodium | Sodium Anhydrous, Nalidixate | Sodium Nalidixic Acid, Anhydrous | Nevigramon | Nalidixate Sodium | Sodium, Nalidixate | Sodium Nalidixic Acid, Monohydrate
Chemical Information
Molecular Formula C12H12N2O3
CAS Registry Number 389-08-2
SMILES CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001---
Blister12.01.06.002; 23.03.01.001---
Bronchospasm10.01.03.012; 22.03.01.004--
Cholestasis09.01.01.001---
Chromatopsia06.02.05.001---
Colour blindness acquired06.02.09.002---
Confusional state17.02.03.005; 19.13.01.001--
Dermatitis23.03.04.002---
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Disorientation17.02.05.015; 19.13.01.002---
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Eosinophilia01.02.04.001--
Epilepsy17.12.03.002---
Erythema23.03.06.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Fontanelle bulging17.02.05.006; 18.04.04.001---
Gastrointestinal pain07.01.05.005--
Glucose-6-phosphate dehydrogenase deficiency01.06.05.001; 03.08.03.001; 14.14.03.001---
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
The 1th Page    1 2 3    Next   Last    Total 3 Pages